A Study of Lebrikizumab (LY3650150) in Adult Participants With Chronic Rhinosinusitis and Nasal Polyps Treated With Intranasal Corticosteroids (CONTRAST-NP)

Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) Clinical Trial

Official title: A Multicentre, Randomized, Double-blind, Placebo-controlled, Parallel Group Phase 3 Efficacy and Safety Study of Lebrikizumab/ LY3650150 in Adults With Chronic Rhinosinusitis With Nasal Polyps on a Background Therapy With Intranasal Corticosteroids

Status Not yet recruiting

Clinical Trial Summary

The main purpose of this study is to evaluate the efficacy and safety of lebrikizumab in adult participants with chronic rhinosinusitis and nasal polyps treated with intranasal corticosteroids. The study will last about 18 months.

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
• Nasal Polyps
• Polyps
• Rhinosinusitis
• Sinusitis

• NCT number: NCT06338995
• Study type: Interventional
• Source: Eli Lilly and Company
• Contact: There may be multiple sites in this clinical trial 1-877-CTLILLY
• Phone: 1-317-615-4559
• Email: ClinicalTrials.gov@lilly.com
• Status: Not yet recruiting
• Phase: Phase 3
• Start date: April 10, 2024
• Completion date: October 25, 2026